English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background   SNRPD1  is a spliceosome-associated protein and has previously been implicated with important roles in cancer development.    Methods  Through analyzing the differential expression patterns and clinical association of splicing associated genes among tumor and tumor adjacent samples across different tumors and among different breast cancer subtypes, we identify the tumor promotive role of SNRPD1 using multiple publicly available datasets. Through pathway, gene ontology enrichment analysis and network construction, we linked the onco-therapeutic role of SNRPD1 with cell cycle. Via a series of experimental studies including knockdown assay, qPCR, western blotting, cell cycle, drug response assay, we confirmed the higher expression of SNPRD1 at both gene and protein expression levels in triple negative breast cancer cells, as well as its roles in promoting cell cycle and chemotherapy response.    Results  Our study revealed that  SNRPD1  over-expression was significantly associated with genes involved in cell cycle, cell mitosis and chromatin replication, and silencing  SNRPD1  in breast cancer cells could lead to halted tumor cell growth and cell cycle arrest at the G 0 /G 1  stage. We also found that triple negative breast cancer cells with reduced  SNRPD1  expression lost certain sensitivity to doxorubicin whereas luminal cancer cells did not.    Conclusions  Our results suggested the prognostic value of  SNRPD1  on breast cancer survival, its potential as the therapeutic target halting cell cycle progression for breast cancer control, and warranted special attention on the combined use of doxorubicin and drugs targeting  SNRPD1 .    Supplementary Information  The online version contains supplementary material available at 10.1186/s12935-021-01932-w.

SNRPD1 confers diagnostic and therapeutic values on breast cancers through cell cycle regulation